who owns the patent for retatrutide FDA approves this year? Predictions & Odds 2026 Product page for Retatrutide /

One study found that the majority of GLP-1 patients regained two-thirds of their prior weight a year after discontinuing their medication

After stopping the medication, however, many consumers report the return of cravings and food noise, along with concerns about weight regain, DuBow said

Critically, AOD-9604 did not produce the metabolic side effects associated with full-length growth hormone, including no insulin resistance or glucose intolerance, no elevation of IGF-1 levels, no fluid retention or joint pain, and no cardiovascular parameter changes

4.14 The Chinese Clinical and Preclinical Long Tail Two early-clinical Chinese programs round out the Phase 1 picture: DYX116 (Jiangsu Deyuan Pharmaceutical, Phase 1 initiated April 2025) and HEC-007 (Sunshine Lake Pharma, Phase 1 initiated August 2025)